<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487082</url>
  </required_header>
  <id_info>
    <org_study_id>65708</org_study_id>
    <nct_id>NCT02487082</nct_id>
  </id_info>
  <brief_title>Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders</brief_title>
  <official_title>Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the combined effect of melatonin and donepezil on&#xD;
      improving sleep and behavior in children with Autism Spectrum Disorders. Melatonin is a&#xD;
      natural neurohormone that helps regulate sleep and wake cycles. Donepezil is used to improve&#xD;
      mental function for people with Alzheimer's disease. Children with Autism Spectrum Disorders&#xD;
      are more likely to have problems sleeping than other children. This difficulty has been&#xD;
      linked to daytime behavioral problems and family stress.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    too few subjects enrolled&#xD;
  </why_stopped>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">January 29, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lethargy/Social Withdrawal</measure>
    <time_frame>Every 5 weeks for a total of 5 times</time_frame>
    <description>Measured by subscale of the Aberrant Behavior Checklist</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stereotypic Behavior</measure>
    <time_frame>Every 5 weeks for a total of 5 times</time_frame>
    <description>Measured by subscale of the Aberrant Behavior Checklist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>Every 5 weeks for a total of 5 times</time_frame>
    <description>Measured by the Children's Sleep Habits Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Global improvement</measure>
    <time_frame>Every 5 weeks for a total of 5 times</time_frame>
    <description>Measured by the Clinical Global Impressions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parent Global improvement</measure>
    <time_frame>Every 5 weeks for a total of 5 times</time_frame>
    <description>Measured by the Parent Reported Global Impressions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) or placebo for 15 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) or placebo for 15 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin and Donepezil</intervention_name>
    <description>The duration depends on group assignment.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The duration depends on group assignment.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Both male and female children&#xD;
&#xD;
          -  Ages 4 to 17 1/2 years&#xD;
&#xD;
          -  Diagnosis with Autism Spectrum Disorder on the basis of the clinical judgment of an&#xD;
             autism specialist, preferably using the Autism Diagnostic Observation Schedule or the&#xD;
             Autism Diagnostic Interview-Revised.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal electroencephalogram in the past month&#xD;
&#xD;
          -  Cardiovascular problems&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Respiratory disease&#xD;
&#xD;
          -  Peptic ulcer disease&#xD;
&#xD;
          -  Renal or hepatic dysfunction (abnormal blood urea nitrogen/creatinine or 2 times&#xD;
             elevated liver transaminases)&#xD;
&#xD;
          -  Urinary tract obstruction&#xD;
&#xD;
          -  Underweight (body mass index &lt; 5th percentile compared to age and sex matched&#xD;
             population)&#xD;
&#xD;
          -  Other serious illness&#xD;
&#xD;
          -  Use of any of the following drugs that might interact with study medications&#xD;
             (anticholinergics, systemic corticosteroids, phenobarbital, peginterferon,&#xD;
             beta-blockers or any drug that may cause arrhythmias). Drugs that induce or inhibit&#xD;
             cytochrome P450 2D6 and cytochrome P450 3A4 (enzymes important for drug metabolism)&#xD;
             will be allowed because any effects of such medications are likely to be lost in&#xD;
             individual variability due to genetic polymorphisms.&#xD;
&#xD;
          -  Use of medications affecting sleep with a half-life of 7 days or more. [Children on&#xD;
             medications affecting sleep with a half-life of less than 7 days (including melatonin&#xD;
             and donepezil) are eligible if they agree to discontinue use for the duration of the&#xD;
             trial.]&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Miller-Horn, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stony Brook University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stony Brook University</investigator_affiliation>
    <investigator_full_name>Jill Miller-Horn</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Autism Spectrum Disorder</keyword>
  <keyword>Children</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Donepezil</keyword>
  <keyword>Sleep disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

